Eli Lilly's run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma n...
Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax
Eli Lilly's run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax Therapeutics for its clinical-stage...
Author: Fierce Biotech
Read Original Article